Skip to main content
Clinical Trials/NCT05248932
NCT05248932
Completed
Phase 4

Role of Norepinephrine Infusion in Preventing Hypotension During Spinal Anesthesia for Cesarean Delivery.

Menoufia University1 site in 1 country40 target enrollmentJanuary 20, 2021

Overview

Phase
Phase 4
Intervention
cardiometry
Conditions
Hypotension
Sponsor
Menoufia University
Enrollment
40
Locations
1
Primary Endpoint
throracic volume variations change from baseline
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This study will be conducted on 40 healthy women having spinal anesthesia for elective cesarean delivery in the operating rooms at Menoufia university hospital.

Detailed Description

Informed written consent will be taken from all subjects included in the study after approval of the study by the local ethical committee. All subjects will be subjected to thorough history taking with risk factors, medical histories, general clinical examination, local clinical examination, laboratory investigations as complete blood count and coagulation profile. Standardized anesthetic care will be provided according to institutional standards, which include fasting, antacid premedication and noninvasive hemodynamic monitoring After arrival in the operating room, patients will be positioned supine with left lateral tilt, pulse oximeter, ECG leads, non-invasive blood pressure cuff and cardiometry leads (4 surface ECG electrodes is attached to the left side of the neck and the lower thorax (approximately at the level of the xiphoid process) will be attached to patient for monitoring of blood pressure (bp), heart rate, fluid responsiveness (thoracic volume variations and stroke volume variations), cardiac index and systemic vascular resistance and values will be recorded as a baseline and every 10 minutes after intrathecal injection. 10 ml/kg/hr lactated ringer solution will be infused to all patients through an 18 gauge intravenous cannula for 30 minutes as a preload before spinal anesthesia then reduced to maintenance infusion of 6 ml/kg/hr. Patients will be then placed in sitting position. After skin disinfection and skin infiltration with lidocaine 1%, spinal anesthesia will be performed with 2ml 0.5% hyperbaric bupivacaine (10 mg) in addition to 0.5 ml fentanyl (25 μg) at L3-L4 or L4-L5. The patient will be then returned to the left-tilted supine position. The study drug regimen will be started immediately after intrathecal injection.

Registry
clinicaltrials.gov
Start Date
January 20, 2021
End Date
June 20, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

mostafa saieed fahim mansour

lecturer

Menoufia University

Eligibility Criteria

Inclusion Criteria

  • ASA I \& II
  • Non laboring
  • Normotensive
  • Elective cesarean delivery under spinal anesthesia.
  • Baseline systolic blood pressure 90-140 mm Hg

Exclusion Criteria

  • Known fetal abnormality.
  • Preexisting or pregnancy-induced hypertension.
  • Known cardiovascular or cerebrovascular disease.
  • Thrombocytopenia, coagulopathy or any contraindication to spinal anesthesia.
  • Weight \<50 or \>100 kg, height \<140 or \>180 cm.
  • Inability or refusal to give informed consent

Arms & Interventions

infusion

patients will receive an infusion of norepinephrine that will be started at 2.5μg/min immediately after intrathecal injection and then manually adjusted according to monitoring of blood pressure (bp), heart rate, fluid responsiveness (thoracic volume variations and stroke volume variations), cardiac index and systemic vascular resistance by using cardiometry, with the objective of maintaining values near baseline

Intervention: cardiometry

infusion

patients will receive an infusion of norepinephrine that will be started at 2.5μg/min immediately after intrathecal injection and then manually adjusted according to monitoring of blood pressure (bp), heart rate, fluid responsiveness (thoracic volume variations and stroke volume variations), cardiac index and systemic vascular resistance by using cardiometry, with the objective of maintaining values near baseline

Intervention: Norepinephrine infusion

bolus

patient with no prophylactic vasopressor and a bolus of 5 μg norepinephrine will be given whenever systolic BP decreases to \<80% of the baseline value.

Intervention: Norepinephrine bolus

bolus

patient with no prophylactic vasopressor and a bolus of 5 μg norepinephrine will be given whenever systolic BP decreases to \<80% of the baseline value.

Intervention: cardiometry

Outcomes

Primary Outcomes

throracic volume variations change from baseline

Time Frame: every 10 minutes up to 1 hour

using cardiometry

cardiac index change from baseline

Time Frame: every 10 minutes up to 1 hour

using cardiometry

systemic vascular resistance change from baseline

Time Frame: every 10 minutes up to 1 hour

using cardiometry

stroke volume variation change from baseline

Time Frame: every 10 minutes and up to 1 hour

using cardiometry

Secondary Outcomes

  • umblical cord gases sample(in the first minute after delivery)
  • APGAR score(after 5 minutes and 10 minutes after delivery)
  • Non invasive MEAN blood pressure(every 10 minutes and up tp 1 hour)
  • Heart rate(every 10 minutes and up to 1 hour)

Study Sites (1)

Loading locations...

Similar Trials